|
Immediate vs. deferred switching from a boosted protease inhibitor (PI/r) based regimen to a dolutegravir (DTG) based regimen in virologically suppressed patients with high cardiovascular risk or age >/=50 years: final 96 weeks results of NEAT 022 study
|
Gatell, J. M.; Assoumou, L.; Moyle, G.; Waters, L.; Johnson, M.; Domingo, P.; Fox, J.; Martinez, E.; Stellbrink, H. J.; Guaraldi, G.; Masia, M.; Gompels, M.; De Wit, S.; Florence, E.; Esser, S.; Raffi, F.; Stephan, C.; Rockstroh, J.; Giacomelli, A.; Vera, J.; Bernardino, J. I.; Winston, A.; Saumoy, M.; Gras, J.; Katlama, C.; Pozniak, A. L.
|
Clinical Infectious Diseases |
2019
|
Article
|
|
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
|
Gatell, J. M.; Assoumou, L.; Moyle, G.; Waters, L.; Johnson, M.; Domingo, P.; Fox, J.; Martinez, E.; Stellbrink, H. J.; Guaraldi, G.; Masia, M.; Gompels, M.; De Wit, S.; Florence, E.; Esser, S.; Raffi, F.; Pozniak, A. L.; NEAT022 Study Group
|
AIDS |
2017
|
Article
|